scholarly journals Rare ovarian neoplasm: Primary precursor B-cell Lymphoblastic Lymphoma involving bilateral ovaries

2020 ◽  
Vol 1 (1) ◽  
pp. 35-38
Author(s):  
K S Prajna ◽  
Keyword(s):  
B Cell ◽  
Female Genital Tract ◽  
Final Diagnosis ◽  
Young Female ◽  
Lymphoblastic Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
Malignant Ovarian Tumor ◽  
Frequent Site ◽  
Neoplasm Primary ◽  
Female Genital

The involvement of the ovary in lymphomatous processes is rare. However, in the female genital tract, the ovary is a frequent site to be involved by the hematological malignancies. Involvement of the ovary by malignant lymphoma can be primary or secondary and is discovered incidentally during a workup for abdominal or pelvic complaints. Most commonly occurring ovarian lymphoma is diffuse large B cell type, whereas the Precursor B Cell Lymphoblastic Lymphomas are extremely rare and previously only 5 cases have been reported. Here, we report a case of clinically suspected malignant ovarian tumor involving bilateral ovaries, which was diagnosed as a primary precursor B-LBL after surgery in a young female. This case highlights the need for careful evaluation of radiologic and morphologic features along with an extensive immunohistochemical panel to arrive at the correct final diagnosis to guide the chemotherapy. Keywords: Non-Hodgkin Lymphoma; Primary Ovarian Precursor B-Cell Lymphoblastic Lymphoma; Primary ovarian lymphoma; Primary ovarian tumors

Niespecyficzny obraz chłoniaka B-komórkowego u dwuipółletniej dziewczynki – opis przypadku

2019 ◽  
Vol 24 (3) ◽  
Author(s):  
Ewa Krasuska-Sławińska ◽  
Izabela Królik-Elgas ◽  
Marzena Stypińska ◽  
Anna Matosek-Rutkowska
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Histopathological Examination ◽  
B Cell Lymphoma ◽  
Final Diagnosis ◽  
Lymphoblastic Lymphoma ◽  
Final Conclusion ◽  
Dental Surgery ◽  
Non Hodgkin Lymphoma ◽  
Primary Location

B-cell lymphoblastic lymphoma which is a type of non-Hodgkin lymphoma is rather uncommon in children. Focal changes in bones in the course of non-Hodgkin lymphoma are mostly secondary changes and their primal location in a bone is rare. PBL (primary bone lymphoma) mainly concerns a thighbone and a tibial bone; the primary location in jaw bones is quite sporadic. In diagnostics, there is mainly magnetic resonance, medical scan (tomography), and above all – histopathological test. There is also chemotherapy by choice, and primary location in a jaw or a mandible significantly advances the prognosis. The aim of the work is to introduce a patient who was definitively diagnosed B-cell lymphoblastic lymphoma from the early B-cells. The girl reported to Laryngological Clinic, Dental Surgery Clinic for Children, Oncological Clinic of Children’s Memorial Health Institute. The cause of the visit was an elevation on the right side of a nose base, present for two months and misdiagnosed by doctors as a post-traumatic swelling in this region. After introducing laboratory and scan diagnostics and taking biopsy from the lesion, a final conclusion was made. Also, a proper treatment according to the protocol for B-cell lymphoblastic lymphoma was introduced. Non-specific B-cell lymphoma picture, as mentioned in the described case, specifically due to location in a jaw bone and a slow pace of growing, may both constitute huge diagnostic problems and deteriorate prognosis. Therefore, it is important to take into account also lymphoma – in such location of a lesion. Moreover, it is worth remembering that the final diagnosis may only be passed on the basis of histopathological examination.

scholarly journals Primary Ovarian Non-Hodgkin Lymphoma- A Diagnostic Challenge with Clinicopathological Study of Eight Cases

2021 ◽  
Author(s):  
Nikita Mulchandani ◽  
Suma Mysore Narayana ◽  
Chennagiri S Premalata ◽  
Mohit Agrawal ◽  
Venkateshaiah Reddihalli Pallavi
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Cell Lymphoma ◽  
Female Genital Tract ◽  
B Cell Lymphoma ◽  
Staging System ◽  
Lymphoblastic Lymphoma ◽  
Molecular Testing ◽  
Diagnostic Challenge ◽  
Non Hodgkin Lymphoma

Introduction: The involvement of the Female Genital Tract (FGT) by lymphoma is extremely rare, with ovaries being most commonly affected. Less than 1% of lymphomas present with ovarian involvement and less than 1.5% of ovarian neoplasms are of lymphoid origin. Secondary involvement of ovary by systemic lymphoma is more common than Primary Ovarian Lymphomas (POL) which is usually Primary Ovarian Non-Hodgkin lymphoma (PONHL) of B-cell lineage. Aim: To understand the clinicopathological and immuno- morphological features of Primary Ovarian Non-Hodgkin lymphoma. Materials and Methods: This was a descriptive retrospective study conducted at Department of Pathology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka. India, for a duration of 14 years between July 2006 to June 2020. Eight cases of PONHL were identified from departmental archives and clinicopathological and Immunohistochemistry (IHC) findings of these tumours were analysed. Results: The PONHL constituted 0.4% of all Non-Hodgkin lymphoma (NHL) reported during the study period. The patients age ranged from 13-60 years with a mean age of 34 years. Among eight cases of PONHL, two cases were of Diffuse Large B-Cell Lymphoma (DLBCL), followed by one case each of High- Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS), Follicular Lymphoma (FL), Burkitt Lymphoma (BL), Plasmablastic Lymphoma (PBL), Precursor B-Lymphoblastic Lymphoma (B-LBL), and precursor T-Lymphoblastic Lymphoma (T-LBL). Seven cases were staged IE (Ann Arbor staging system) while one case was designated as stage IIE. Conclusion: This was probably the first study on PONHL from India. The diagnosis of PONHL is challenging unless there is a high index of suspicion as these patients present with non specific pelvic symptoms and can be misdiagnosed as other epithelial, stromal or germ cell ovarian neoplasm which differs in treatment and prognosis. Histological examination with IHC and molecular testing are essential to establish a diagnosis.

Clinical Outcome of 119 Children with Non-Hodgkin Lymphoma Treated in a Single Center in China

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 5299-5299
Author(s):  
Yonghong Zhang ◽  
Ling Jin ◽  
Jing Yang ◽  
Yanlong Duan ◽  
Chunjv Zhou ◽  
...  
Keyword(s):  
Bone Marrow ◽  
T Cell ◽  
B Cell ◽  
Hodgkin Lymphoma ◽  
Nk Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Lymphoblastic Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
Pathologic Classification

Abstract One hundred and nineteen children with non-Hodgkin lymphoma were treated between February 2003 and December 2006 in Beijing Children’s Hospital on BCH-2003-NHL protocol. The diagnosis was made by histopathology of the biopsied tissue and/or bone marrow, and disease was classified according to WHO-2001 pathologic classification. We applied modified LMB89 protocol to cases with B-cell lymphoma; modified BFM90-ALL protocol for lymphoblastic lymphoma and cutaneous T-cell/NK cell lymphoma; and modified BFM90-ALCL protocol for anaplastic large-cell lymphoma (ALCL). There were 50 cases (42%) of B cell lymphoma including 32 cases of Burkitt¡’s lymphoma, 10 cases of Burkitt-like lymphoma and 8 cases of diffuse large B cell lymphoma; 44 cases (37%) of lymphoblastic lymphoma; 19 cases (16%) of ALCL; and 6 cases (5%) of cutaneous T-cell/NK cell lymphoma. The 85 boys and 34 girls (ratio, 2.5:1) ranged in age from 2 to 15 years (median, 7.8 years) at diagnosis. B cell lymphoma typically presented as abdomen mass and acute abdomen; nasopharynx and tonsil were also common sites of involvement. Lymphoblastic lymphoma generally presented with mediastinal mass and bone marrow involvement. There was no typical presentation for ALCL. According to the St. Jude staging system, 19 cases had stage I–II, and 94 cases stage III–VI diseases (exclude 6 cases of cutaneous T-cell/NK cell lymphoma). Seven cases had CNS involvement and 25 cases involved bone marrow. The treatment duration was 2 to 8 months for B-cell lymphoma, 2.5 to 3 years for lymphoblastic lymphoma and 1 to 1.5 years for ALCL. The follow-up rate was 100% and median observation period was 23 months. The overall survival (OS) at 3 years was 90.7% and the 3-year event-free survival (EFS) estimate was 82.3%. For B-cell lymphoma, 3-year OS was 88.68% and 3-year EFS was 81.8%. For lymphoblastoma lymphoma, the rates were 89.3% and 69.4%, respectively. All cases of ALCL are alive with on undergoing treatment for relapse. Patients with ALCL achieved the best 3-year OS (100%) and had 3-year EFS of 94.2%. Grade 3 or 4 bone marrow suppression occurred in 97.5% of patients with B-cell lymphoma, 100% of those with lymphoblastic lymphoma and 89.5% of cases with ALCL. As of to date, 11 patients have died, the causes of death include infection (n=4), abandonment of therapy (n=6) and relapse (n=1). Univarate analysis showed that stage IV disease, failure to achieve complete remission after 3 months of treatment, and bulky mass are were associated with poor prognosis £all P values <0.05£©. In summary, we have achieved excellent treatment results using modified international protocols. Infection and financial problem remained the main reasons of treatment failure.

scholarly journals Primary Orbital Lymphoma – A Rare Challenging Diagnostic Entity

2020 ◽  
pp. 18-21
Author(s):  
Nisha Marwah ◽  
Niti Dalal ◽  
Manali Satiza ◽  
Sunita Singh
Keyword(s):  
B Cell ◽  
Lymphoproliferative Disorder ◽  
Histopathological Examination ◽  
Final Diagnosis ◽  
Primary Diagnosis ◽  
Cell Type ◽  
Non Hodgkin Lymphoma ◽  
Immunohistochemical Markers ◽  
Orbital Lymphoma ◽  
Hodgkin's Lymphomas

The diagnosis of lymphoproliferative disorder of orbit is quite challenging as both Pseudolymphomas and Non‑Hodgkin’s lymphomas can occur in orbit. Primary orbital lymphoma is a rare entity comprising of 1-2% of Non‑Hodgkin’s lymphoma, majority of them are B‑cell type. It is a slow growing tumor. It presents in the age group of 50–70 years, with a slight female preponderance. Proptosis is the most common presentation. We, herein, report a case of 48 years old male presenting with right non-axial proptosis, watering of eye, blurring of vision and redness for the last 9 months. After thorough clinical and radiological evaluation, a biopsy was taken for histopathological examination. A primary diagnosis of Lymphoproliferative Disorder was made. Following this, a panel of immunohistochemical markers was applied and a final diagnosis of Non-Hodgkin Lymphoma, B-cell type was given.

scholarly journals Outcome and survival in children with Non-Hodgkin’s lymphoma

2019 ◽  
Vol 7 (1) ◽  
Author(s):  
Tahani Awad Elkarim Elfadl ◽  
Ibrahim Abosoudah ◽  
Mohammed Bayoumy ◽  
Ali Al Harbi ◽  
Muhammad Matloob Alam ◽  
...  
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large Cell ◽  
Lymphoblastic Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
Large B Cell Lymphoma ◽  
King Faisal Specialist Hospital ◽  
Large Cell Lymphoma

Background Non-Hodgkin lymphoma is the third most common malignant tumor in children. It includes four major subtypes: Burkitt Lymphoma (BL), Lymphoblastic Lymphoma (LL), Diffuse Large B-cell Lymphoma (DLBL) and Anaplastic Large Cell Lymphoma (ALCL). The use of multidrug chemotherapy, radiation therapy, biologic agents, and improved diagnostic and supportive care resulted in better cure rates. Objective This study is to report prognosis and outcome of Non-Hodgkin lymphoma (NHL) patients at tertiary health care facility in King Faisal Specialist Hospital and Research Center, Jeddah (KFSHRC-J). Materials and Method A retrospective cross-sectional study of all eligible patients with Non-Hodgkin lymphoma (NHL), admitted, diagnosed and managed at King Faisal Specialist Hospital and Research Center, Jeddah from Jan 2005 to December 2016, previously untreated, with biopsy proven NHL and Age ≤ 15 years at diagnosis. Clinical data Research Form used to collect patient’s data from medical records. Demographic, Clinical and Survival data analysed using Statistical Package for Social Sciences. Results Thirty-one pediatric patients with biopsy proven Non-Hodgkin lymphoma (NHL) fulfilled the inclusion criteria. Twenty-six (80.6%) were males. Nineteen (61.3%) patients were ≤ 10 years of age at diagnosis, while 12 (38.7%) were>10 years of age. The mean age at diagnosis was 8.1years. The commonest primary site is abdomen (n=19, 61.3%), followed by Head & Neck (n=9, 28.1%), mediastinum (n=1, 3.1%), primary CNS (n=1, 3.1%), bone (n=1, 3.1%) and skin (n=1, 3.1%). Regarding histology 19 (61.3%) had Burkitt Lymphoma (BL), 6 (19.4%) had Diffuse Large B-cell Lymphoma (DLBL), 2(6.4%) had T-cell Lymphoblastic Lymphoma, 2 (6.4%) had T-cell rich B Cell Lymphoma, 1 (3.1%) had B-cell Lymphoma not otherwise specified and 1 (3.1%) had Cutaneous Anaplastic Large Cell Lymphoma (ALCL). Predominantly, patients presented in advanced stages III (n=18, 60%) and IV (n=10, 33%).Twenty-five (77.8%) patients completed treatment and are well to date while six of the patients (18.6%) died during the study period. Conclusion Children admitted to the (KFSHRC-J) appeared affected by non-Hodgkin Lymphoma at a younger age, with a higher incidence of Burkitt's Lymphoma. The predominant presenting site is abdomen followed by head/neck. They present mostly with advance disease. Survival rates are similar to those described in the literature of developed countries.

Non-Hodgkin Lymphomas in Children and Adolescents

2020 ◽  
pp. 142-156
Author(s):  
Véronique Minard-Colin ◽  
Catherine Patte
Keyword(s):  
B Cell ◽  
Hodgkin Lymphoma ◽  
Burkitt Lymphoma ◽  
Cell Lymphoma ◽  
Survival Rates ◽  
B Cell Lymphoma ◽  
Large Cell ◽  
Lymphoblastic Lymphoma ◽  
Non Hodgkin Lymphoma ◽  
Innovative Therapies

Non-Hodgkin lymphoma (NHL) is the fourth most common malignancy in children, with an even higher incidence in adolescents, and is primarily represented by only a few histological subtypes. Dramatic progress has been achieved, with survival rates exceeding 80%. Most patients with Burkitt lymphoma and diffuse large B-cell lymphoma are cured with short, intensive, pulse chemotherapy. The benefit of the addition of rituximab has been demonstrated for high-risk B-NHL and primary mediastinal B-cell lymphoma. Lymphoblastic lymphoma is treated with intensive, semi-continuous, longer ‘leukaemia-derived’ protocols. Relapses in B-cell and lymphoblastic lymphomas are rare and infrequently curable, even with intensive approaches. Event-free survival rates of about 75% have been achieved in anaplastic large-cell lymphomas with various regimens, including generally a short, intensive ‘B-like’ regimen. The role of immunity appears important in prognosis and needs further exploration in therapy. Anaplastic lymphoma kinase (ALK) inhibitor therapeutic approaches are currently being investigated. For all these paediatric lymphomas, the intensity of induction/consolidation treatments correlates with a high rate of immediate toxicities, but due to low cumulative doses of anthracyclines and alkylating agents, minimal or no long-term toxicity is expected. Challenges that remain include defining the value of prognostic factors, such as early response on positron emission tomography (PET)/computed tomography (CT) and monitoring of minimal disseminated and residual disease, utilizing new biological technologies to improve risk stratification and the development of innovative therapies, both at frontline and relapse. non-Hodgkin lymphoma, NHL, European Intergroup for Childhood NHL, EICNHL, Burkitt lymphoma, anaplastic large-cell lymphoma, ALK, lymphoblastic lymphoma

scholarly journals MALIGNANT MELANOMA OF UTERINE CERVIX IN A YOUNG FEMALE

2019 ◽  
pp. 1-2
Author(s):  
Purvi Rathod
Keyword(s):  
Malignant Melanoma ◽  
Uterine Cervix ◽  
Genital Tract ◽  
External Beam Radiotherapy ◽  
Female Genital Tract ◽  
Young Female ◽  
Rare Cancer ◽  
Female Genital

Malignant melanoma is a rare cancer, its incidence being 1% of all cancers. Malignant melanoma of the female genital tract is even rarer with incidence of 3% to 7% of all malignant melanomas. It usually occurs in postmenopausal women. We present a case of malignant melanoma of the uterine cervix in a multiparous premenopausal 29 year old female. She underwent a modified radical hysterectomy. She was stage III and was treated with external beam radiotherapy to the pelvis followed by brachytherapy. Since then the patient was on regular follow up until she developed lung metastasis. Malignant melanoma of the cervix has very less data in literature. Through this case report we will emphasize on the role of radiotherapy in malignant melanoma of uterine cervix

Sign in / Sign up

Export Citation Format

Share Document